XML 13 R39.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Otsuka) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Dec. 31, 2012
Mar. 31, 2013
Abilify [Member]
Mar. 31, 2012
Abilify [Member]
Mar. 31, 2013
Otsuka [Member]
Abilify [Member]
Mar. 31, 2012
Otsuka [Member]
Abilify [Member]
Dec. 31, 2015
Otsuka [Member]
Abilify [Member]
Dec. 31, 2014
Otsuka [Member]
Abilify [Member]
Dec. 31, 2013
Otsuka [Member]
Abilify [Member]
Mar. 31, 2013
Otsuka [Member]
Abilify [Member]
Extension payment [Member]
Mar. 31, 2012
Otsuka [Member]
Abilify [Member]
Extension payment [Member]
Dec. 31, 2012
Otsuka [Member]
Abilify [Member]
Extension payment [Member]
Apr. 30, 2009
Otsuka [Member]
Abilify [Member]
Extension payment [Member]
Mar. 31, 2012
Otsuka [Member]
Abilify [Member]
Upfront, milestone and other licensing payments [Member]
Mar. 31, 2013
Otsuka [Member]
Abilify, Sprycel and Ixempra [Member]
Mar. 31, 2012
Otsuka [Member]
Abilify, Sprycel and Ixempra [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Mar. 31, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Dec. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Dec. 31, 2012
Otsuka [Member]
United States [Member]
Abilify [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Up To 2 Point 7 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 2 Point 7 Billion And 3 Point 2 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 3 Point 2 Billion And 3 Point 7 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 3 Point 7 Billion And 4 Point 0 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Between 4 Point 0 Billion And 4 Point 2 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
United States [Member]
Abilify [Member]
Annual Net Sales Over 4 Point 2 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
France, Germany, Spain, United Kingdom And Italy [Member]
Abilify [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Abilify [Member]
Annual Net Sales Up To 2 Point 7 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Abilify [Member]
Annual Net Sales Between 2 Point 7 Billion And 3 Point 2 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Abilify [Member]
Annual Net Sales Between 3 Point 2 Billion And 3 Point 7 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Abilify [Member]
Annual Net Sales Between 3 Point 7 Billion And 4 Point 0 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Abilify [Member]
Annual Net Sales Between 4 Point 0 Billion And 4 Point 2 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Abilify [Member]
Annual Net Sales Over 4 Point 2 Billion [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Mar. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Operating expense up to $175 million [Member]
Mar. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Operating expenses over $175 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales up to $400 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales up to $400 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $400 and $600 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $400 and $600 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $600 and $800 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual net sales between $600 and $800 million [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Net Sales Between $800 Million And $1 Billion [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Net Sales Between $800 Million And $1 Billion [Member]
Dec. 31, 2013
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Sales In Excess Of $1 Billion [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
Sprycel and Ixempra [Member]
Annual Sales In Excess Of $1 Billion [Member]
Alliances and Collaborations Statement [Line Items]                                                                                                
Percentage of net sales recognized from collaboration                                       35.00% 51.50% 50.00% 20.00% 7.00% 2.00% 1.00% 20.00% 65.00%                                        
Percentage of operating expense reimbursements from collaboration                                         30.00%                               20.00% 1.00%                    
Payment to extend term of commercialization agreement                           $ 400                                                                    
Percentage of net sales payable to collaboration partner                                   1.50%                                         65.00% 30.00% 12.00% 5.00% 3.00% 3.00% 2.00% 2.00% 1.00% 1.00%
Range of sales at which a given percentage will be paid to collaboration partner - maximum                                                         2,700 3,200 3,700 4,000 4,200           400   600   800   1,000      
Range of sales at which a given percentage will be paid to collaboration partner - minimum                                                           2,700 3,200 3,700 4,000 4,200             400   600   800   1,000  
Amount of operating expense at or below which collaboration partner will reimburse given percentage                                                                         175                      
Amount of operating expense over which collaboration partner will reimburse given percentage                                                                           175                    
Abilify* net sales, including amortization of extension payment 3,831 5,251   522 621 522 621                                                                                  
Oncology Products collaboration fee expense                                                                     70 32                        
Royalty expense                                   17 17                                                          
Commercialization expense reimbursement to/(from) Otsuka                               (6) (24)                                                              
Amortization (income)/expense - extension payment                     16 16                                                                        
Amortization expense - upfront, milestone and other licensing payments 216 101                         2                                                                  
Other assets - extension payment 975   904               137   153                                                                      
Other intangible assets - upfront, milestone and other licensing payments 8,570   8,778                                                                                          
Maximum reimbursement of operating expenses payable to a collaboration partner               8 56 82                                                                            
Payment made to Otsuka to assume full responsiblity for providing and funding all sales efforts.           $ 27                                                                                    
The percentage of sales recognized by the Company when it is the principal in the customer sale. 100.00%